- Home
- PBPB vs PRQR Comparison
PBPB vs PRQR Comparison
Compare PBPB & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- PRQR
- Stock Information
- Founded
- PBPB 1977
- PRQR 2012
- Country
- PBPB United States
- PRQR Netherlands
- Employees
- PBPB N/A
- PRQR N/A
- Industry
- PBPB Restaurants
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- PRQR Health Care
- Exchange
- PBPB Nasdaq
- PRQR Nasdaq
- Market Cap
- PBPB 305.0M
- PRQR 179.1M
- IPO Year
- PBPB 2013
- PRQR 2014
- Fundamental
- Price
- PBPB $12.65
- PRQR $2.35
- Analyst Decision
- PBPB Strong Buy
- PRQR Strong Buy
- Analyst Count
- PBPB 3
- PRQR 8
- Target Price
- PBPB $15.67
- PRQR $8.88
- AVG Volume (30 Days)
- PBPB 246.6K
- PRQR 365.1K
- Earning Date
- PBPB 08-07-2025
- PRQR 08-07-2025
- Dividend Yield
- PBPB N/A
- PRQR N/A
- EPS Growth
- PBPB 1009.90
- PRQR N/A
- EPS
- PBPB 1.39
- PRQR N/A
- Revenue
- PBPB $465,126,000.00
- PRQR $21,212,711.00
- Revenue This Year
- PBPB $4.74
- PRQR N/A
- Revenue Next Year
- PBPB $4.48
- PRQR N/A
- P/E Ratio
- PBPB $9.09
- PRQR N/A
- Revenue Growth
- PBPB N/A
- PRQR 85.91
- 52 Week Low
- PBPB $6.28
- PRQR $1.07
- 52 Week High
- PBPB $13.48
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PBPB 68.87
- PRQR 66.90
- Support Level
- PBPB $12.38
- PRQR $2.10
- Resistance Level
- PBPB $12.85
- PRQR $2.18
- Average True Range (ATR)
- PBPB 0.41
- PRQR 0.13
- MACD
- PBPB 0.00
- PRQR 0.01
- Stochastic Oscillator
- PBPB 84.11
- PRQR 56.92
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.